NCT05961111招募中早期 1 期
An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年6月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Subject incidence of adverse events
研究概览
简要总结
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with solid tumors clearly diagnosed by histology and/or cytology.
- •Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
- •Age 18 to 75 years.
- •Subjects with ECoG score of 0-
- •Expected survival of 3 months or more.
- •Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral or intraperitoneal drug delivery.
- •Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets (PLT) ≥ 80 × 109/L, and hemoglobin (Hb) ≥ 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum c) serum total bilirubin (TBIL) ≤ 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) ≤ 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values.
- •No absolute or relative centasis contraindiction.
- •Eligible patients of childbearing potential must agree to use a reliable method of contraception with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment.
- •Subjects voluntarily sign an informed consent form and are in good compliance.
排除标准
- •Have had any serious adverse reactions associated with immunotherapy.
- •Subjects with any severe and/or uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470 ms and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (≥ CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein ≥++ and confirmed 24-hour urine protein quantification > 1.0 g.
- •Patients with past history of type I diabetes mellitus or HIV.
- •Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy.
- •Patients with severe prior interstitial lung changes (as determined by the investigator).
- •Patients with active tuberculosis and a strong positive OT test.
- •Patients with active bleeding or severe coagulation dysfunction.
- •Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose.
- •Have not recovered to CTCAE 4.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy.
- •Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance.
- •Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment.
- •Pregnant, lactating and planning to have children within six months.
- •Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.
研究组 & 干预措施
R130 Treatment Group
Experimental
Every 7-14 days,1-2 ml R130 （concentration of 1x10^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors
干预措施: Recombinant oncolytic herpes simplex virus type 1 (R130) (Drug)
结局指标
主要结局
Subject incidence of adverse events
时间窗: Up to 6 months
To characterize the safety profile of R130 injection in patients with advanced solid tumors as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0),such as fever, fatigue, flu like symptoms, chills, Injection site reaction,etc.
Subject incidence of laboratory abnormalities
时间窗: Up to 1 month
Systemic Immune Response
时间窗: Up to 6 months
Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa，IFNγ, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)
次要结局
- Disease Assessment for Disease Control Rate(Every 10 weeks for 12 months)
- Disease Assessment for Duration of Response(Every 10 weeks for 12 months)
- Quality of Life Assessment(Every 6 weeks for 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial CancerEndometrial CancerAdvanced CancerCervical CancerNCT05812677Shanghai Yunying Medical Technology20
招募中
早期 1 期
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue TumorsOsteosarcomaSarcoma,Soft TissueBone TumorSarcomaNCT05851456Shanghai Yunying Medical Technology20
招募中
早期 1 期
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid TumorsCarcinomaGynecologic CancerPancreatic CancerColorectal CancerGastric CancerSarcomaBreast CancerLiver CancerLung CancerNCT05860374Shanghai Yunying Medical Technology20
招募中
2 期
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUCUpper Urinary Tract Urothelial CarcinomaRenal InsufficiencySolitary KidneyNCT06354231Fudan University20
招募中
早期 1 期
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid TumorsBronchial CancerNon Small Cell Lung CancerLung CancerHead and Neck CancerBreast CancerColorectal CancerOvarian CancerGastric CancerSarcomaLiver CancerPancreatic CancerSmall Cell Lung CancerNCT05886075Shanghai Yunying Medical Technology24